Comments
Drug-maker Cipla’s profit after tax stood at Rs 475 crore in the three months ended June 30, 2013, up about 18 per cent from Rs 401 crore in the corresponding period last year.
Gross revenues stood at Rs 2,492 crore (Rs 1,989 crore), up 25 per cent. The company’s domestic revenue grew over 16 per cent, at Rs 1,132 crore (Rs 970 crore). The growth in domestic revenues was largely on the back of growth in anti-asthma, antibiotics and anti-infectives, besides cardio-vascular drugs, the company said.
Exports of finished drugs grew over 27 per cent at Rs 1034 crore. But exports of active pharmaceutical ingredients fell by 13 per cent to 146 crore, it added.
The growth in export revenues was on the back of anti-retroviral , anti-asthma and anti-allergic segments, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.